<DOC>
	<DOCNO>NCT00670358</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stimulate immune system different way stop cancer cell grow . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving lenalidomide together rituximab combination chemotherapy may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose lenalidomide give together rituximab combination chemotherapy see well work treat patient newly diagnose stage II , stage III , stage IV diffuse large cell follicular B-cell lymphoma .</brief_summary>
	<brief_title>Lenalidomide , Rituximab , Combination Chemotherapy Treating Patients With Newly Diagnosed Stage II , Stage III , Stage IV Diffuse Large Cell Follicular B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose lenalidomide give combination rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone patient newly diagnose stage II-IV diffuse large cell grade 3 follicular B-cell lymphoma . ( Phase I ) - To assess efficacy regimen , term event-free survival response rate , patient . ( Phase II ) - To assess safety regimen patient . ( Phase II ) Secondary - To assess host immune function baseline treatment correlate parameter tumor response event-free survival . OUTLINE : This multicenter , phase I dose-escalation study lenalidomide follow phase II study . - Phase I : Patients receive rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 , oral prednisone day 1-5 , oral lenalidomide day 1-10 . Patients also receive pegfilgrastim subcutaneously day 2 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Phase II : Patients receive lenalidomide maximum tolerate dose determined phase I rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone , pegfilgrastim phase I . Blood collect baseline , course 3 , completion study treatment translational research study . Research study include immune function cytokine analysis , T- B- quantitative lymphocyte analysis , single nucleotide polymorphism analysis . After completion study therapy , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large cell grade 3A/B follicular lymphoma Newly diagnose disease Stage II , III , IV disease Measurable disease , define ≥ 1 lesion ≥ 1.5 cm one diameter , detect CT scan PETCT scan ( PET/CT fusion ) CD20positive disease No posttransplant lymphoproliferative disorder ( PTLD ) No CNS lymphoma cerebrospinal fluid involvement malignant lymphoma cell PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) OR direct bilirubin normal Alkaline phosphatase ≤ 3 time ULN ( 5 time ULN direct liver involvement lymphoma ) AST ≤ 3 time ULN ( 5 time ULN direct liver involvement lymphoma ) Creatinine ≤ 2 time ULN Not pregnant nursing Negative pregnancy test Fertile female patient must use effective doublemethod contraception ≥ 28 day , , ≥ 28 day completion study therapy Fertile male patient must use effective contraception ≥ 28 day completion study therapy , even successful vasectomy No blood , sperm , semen donation ≥ 28 day completion study therapy Willing return enrol institution followup Willing provide blood sample translational research purpose No comorbid systemic illness severe concurrent disease , judgment investigator , would preclude study entry significantly interfere proper assessment safety toxicity prescribe study regimen No know HIV positivity Not immunocompromised No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would preclude compliance study requirement No active malignancy , except localize nonmelanotic skin cancer cancer , judgment investigator , treat curative intent interfere study treatment plan response assessment No myocardial infarction within past 6 month No congestive heart failure require ongoing maintenance therapy lifethreatening ventricular arrhythmias Ejection fraction ≥ 45 % MUGA ECHO No history life threaten recurrent thrombosis/embolism ( unless anticoagulation therapy study treatment ) PRIOR CONCURRENT THERAPY : No prior radiotherapy ≥ 25 % bone marrow No concurrent erythroidstimulating agent ( e.g. , Procrit , Aranesp ) No concurrent treatment lymphoma No concurrent radiotherapy , chemotherapy , immunotherapy another active malignancy Able receive concurrent prophylactic anticoagulation therapy ( e.g. , lowdose aspirin [ 81 mg ] daily alternative prophylaxis [ e.g. , warfarin low molecular weight heparin ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>